IL‐1β and IL‐18: inflammatory markers or mediators of hypertension?
Open Access
- 1 December 2014
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 171 (24), 5589-5602
- https://doi.org/10.1111/bph.12876
Abstract
Chronic inflammation in the kidneys and vascular wall is a major contributor to hypertension. However, the stimuli and cellular mechanisms responsible for such inflammatory responses remain poorly defined. Inflammasomes are crucial initiators of sterile inflammation in other diseases such as rheumatoid arthritis and gout. These pattern recognition receptors detect host-derived danger-associated molecular patterns (DAMPs), such as microcrystals and reactive oxygen species, and respond by inducing activation of caspase-1. Caspase-1 then processes the cytokines pro-IL-1β and pro-IL-18 into their active forms thus triggering inflammation. While IL-1β and IL-18 are known to be elevated in hypertensive patients, no studies have examined whether this occurs downstream of inflammasome activation or whether inhibition of inflammasome and/or IL-1β/IL-18 signalling prevents hypertension. In this review, we will discuss some known actions of IL-1β and IL-18 on leukocyte and vessel wall function that could potentially underlie a prohypertensive role for these cytokines. We will describe the major classes of inflammasome-activating DAMPs and present evidence that at least some of these are elevated in the setting of hypertension. Finally, we will provide information on drugs that are currently used to inhibit inflammasome/IL-1β/IL-18 signalling and how these might ultimately be used as therapeutic agents for the clinical management of hypertension.Funding Information
- National Health & Medical Research Council of Australia (350327)
- National Health & Medical Research Council of Australia (APP1006017)
- National Health & Medical Research Council of Australia (APP1062721)
This publication has 153 references indexed in Scilit:
- Inhibition of TNF in the Brain Reverses Alterations in RAS Components and Attenuates Angiotensin II-Induced HypertensionPLOS ONE, 2013
- NLRP3 inflammasomes link inflammation and metabolic diseaseTrends in Immunology, 2011
- The InflammasomesCell, 2010
- Ac-YVAD-CMK Decreases Blood–Brain Barrier Degradation by Inhibiting Caspase-1 Activation of Interleukin-1β in Intracerebral Hemorrhage Mouse ModelTranslational Stroke Research, 2009
- Inflammatory arthritis in caspase 1 gene–deficient mice: Contribution of proteinase 3 to caspase 1–independent production of bioactive interleukin‐1βArthritis & Rheumatism, 2009
- Caspase 1–independent activation of interleukin‐1β in neutrophil‐predominant inflammationArthritis & Rheumatism, 2009
- Effect of Allopurinol on Blood Pressure of Adolescents With Newly Diagnosed Essential HypertensionJAMA, 2008
- Selective P2X7 receptor antagonists for chronic inflammation and painPurinergic Signalling, 2008
- Interleukin 1-beta (IL-1β) enhances contractile responses in endothelium-denuded aorta from hypertensive, but not normotensive, ratsVascular Pharmacology, 2007
- Reactive oxygen species in vascular biology: implications in hypertensionHistochemistry and Cell Biology, 2004